Alzamend Neuro
ALZN
Alzamend Neuro (ALZN) news
Recent news
Alzamend Neuro - files to register resale of up to 98.4 mln common shares by selling stockholder - SEC filing
AInvest Wire · Aug 21, 2026ImportantAlzamend Neuro shares rise 450% on partnership for PTSD treatment mid-stage study
Alzamend Neuro shares rise 450% on partnership for PTSD treatment mid-stage study Introduction: Alzamend Neuro (NASDAQ: ALZN), a clinical-stage biopharmaceutical company specializing in the development of treatments for Alzheimer's disease, Bipolar disorder, Major Depressive Disorder (MDD), and…
AInvest Wire · Aug 19, 2024Alzamend Neuro receives FDA ‘study may proceed’ notification for a Phase IIa clinical trial of Al001
AInvest Wire · Dec 11, 2023ImportantAlzamend Neuro surges 33% premarket after Benzinga reported the Co. has received a "Study May Proceed" letter from the FDA for the initiation of study AL001-MDD01
AInvest Wire · Nov 20, 2023ImportantAlzamend Neuro slumps 29% premarket after directors approved a 1-for-15 reverse stock split of Alzamend’s common stock
AInvest Wire · Oct 30, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.